Latest news with #ABBV-706
Yahoo
03-06-2025
- Business
- Yahoo
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers
AbbVie recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with overall market stability. The market awaited significant financial updates, such as Nvidia's anticipated earnings report, contributing to a general holding pattern in stock movements. While AbbVie's steady price echoes broader market trends, the therapeutic advancements underscore the company's ongoing commitment to developing innovative treatments. Every company has risks, and we've spotted 5 weaknesses for AbbVie you should know about. We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent announcements regarding AbbVie's investigational therapies, including Temab-A and ABBV-706, stand to reinforce the narrative focused on pipeline growth and market expansion. These advancements could catalyze future revenues, particularly within the obesity and oncology sectors. This aligns with AbbVie's aim to leverage clinical progress to enhance financial outcomes, though immediate impacts on revenue and earnings forecasts might require more time to materialize. Given that the share price remained flat despite the positive pipeline developments, it appears the market is waiting for further validation of potential revenue contributions. Over the past five years, AbbVie's total shareholder return, combining share price appreciation and dividends, reached 150.37%, reflecting a robust long-term performance. In comparison, the company outperformed the US Biotechs industry, which saw a decline of 10.4% over the last year, highlighting AbbVie's relative strength in a challenging market environment. Currently, AbbVie's share price trades at approximately US$187.15, positioning it at a discount relative to the consensus price target of US$210.68. This indicates an 11.2% potential upside according to the analysts' expectations. The stability in the stock price, despite the recent news on clinical advancements, suggests investors might be holding out for more substantial financial data that aligns with the projected growth in revenues, where analysts foresee a progression to around US$70 billion by 2028. Unlock comprehensive insights into our analysis of AbbVie stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABBV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
